Ibio Inc (NYSEMKT:IBIO) Institutional Investor Sentiment

December 8, 2017 - By Clifton Ray

 Ibio Inc (NYSEMKT:IBIO) Institutional Investor Sentiment

Sentiment for Ibio Inc (NYSEMKT:IBIO)

Ibio Inc (NYSEMKT:IBIO) institutional sentiment decreased to 1 in 2017 Q2. Its down -2.00, from 3 in 2017Q1. The ratio has worsened, as 5 active investment managers started new and increased holdings, while 5 sold and trimmed holdings in Ibio Inc. The active investment managers in our partner’s database now have: 2.83 million shares, down from 2.99 million shares in 2017Q1. Also, the number of active investment managers holding Ibio Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 0 Reduced: 5 Increased: 2 New Position: 3.

iBio, Inc., a biotechnology company, focuses on developing and commercializing pharmaceutical product applications using its platform in the United States and internationally. The company has market cap of $17.31 million. The Company’s lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It currently has negative earnings. It is also developing vaccine candidates for third parties.

The stock decreased 5.12% or $0.01 during the last trading session, reaching $0.15. About 1.23 million shares traded or 55.48% up from the average. iBio, Inc. (NYSEMKT:IBIO) has declined 45.59% since December 8, 2016 and is downtrending. It has underperformed by 62.29% the S&P500.

Signaturefd Llc holds 0.01% of its portfolio in iBio, Inc. for 152,910 shares. Bank Of America Corp De owns 1,122 shares or 0% of their US portfolio. Moreover, Bank Of New York Mellon Corp has 0% invested in the company for 69,463 shares. The New York-based Blackrock Inc. has invested 0% in the stock. Citadel Advisors Llc, a Illinois-based fund reported 55,878 shares.#img1#

Another recent and important iBio, Inc. (NYSEAMERICAN:IBIO) news was published by Globenewswire.com which published an article titled: “iBio, Inc. Announces Proposed Public Offering of Common Stock” on November 28, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.